RNA-binding protein FUS explained

RNA-binding protein FUS/TLS (FUsed in Sarcoma/Translocated in LipoSarcoma), also known as heterogeneous nuclear ribonucleoprotein P2 is a protein that in humans is encoded by the FUS gene.[1] [2] [3] [4] [5] [6]

Discovery

FUS/TLS was initially identified as a fusion protein (FUS-CHOP) produced as a result of chromosomal translocations in human cancers, especially liposarcomas.[5] In these instances, the promoter and N-terminal part of FUS/TLS is translocated to the C-terminal domain of various DNA-binding transcription factors (e.g. CHOP) conferring a strong transcriptional activation domain onto the fusion proteins.[7]

FUS/TLS was independently identified as the hnRNP P2 protein, a subunit of a complex involved in the maturation of pre-mRNA.[8]

Structure

FUS/TLS is a member of the FET protein family that also includes the EWS protein, the TATA-binding protein TBP-associated factor TAFII68/TAF15, and the Drosophila cabeza/SARF protein.[9] [10]

FUS/TLS, EWS and TAF15 have a similar structure, characterised by an N-terminal QGSY-rich region, a highly conserved RNA recognition motif (RRM), multiple RGG repeats, which are extensively demethylated at arginine residues[11] and a C-terminal zinc finger motif.[3] [5] [9] [12]

Function

The N-terminal end of FUS appears to be involved in transcriptional activation, while the C-terminal end is involved in protein and RNA binding. In addition recognition sites for the transcription factors AP2, GCF, Sp1 have been identified in FUS.[13]

Consistently, in vitro studies have shown that FUS/TLS binds RNA, single-stranded DNA and (with lower affinity) double-stranded DNA.[3] [5] [14] [15] [16] [17] The sequence specificity of FUS/TLS binding to RNA or DNA has not been well established; however, using in vitro selection (SELEX), a common GGUG motif has been identified in approximately half of the RNA sequences bound by FUS/TLS.[18] A later proposal was that the GGUG motif is recognised by the zinc finger domain and not the RRM (80). Additionally, FUS/TLS has been found to bind a relatively long region in the 3′ untranslated region (UTR) of the actin-stabilising protein Nd1-L mRNA, suggesting that rather than recognising specific short sequences, FUS/TLS interacts with multiple RNA-binding motifs or recognises secondary conformations.[19] FUS/TLS has also been proposed to bind human telomeric RNA (UUAGGG)4 and single-stranded human telomeric DNA in vitro.[20]

Beyond nucleic acid binding, FUS/TLS was also found to associate with both general and more specialized protein factors to influence the initiation of transcription.[21] Indeed, FUS/TLS interacts with several nuclear receptors.[22] and with gene-specific transcription factors such as Spi-1/PU.1.[23] or NF-κB.[24] It also associates with the general transcriptional machinery and may influence transcription initiation and promoter selection by interacting with RNA polymerase II and the TFIID complex.[25] [26] [27] Recently, FUS/TLS was also shown to repress the transcription of RNAP III genes and to co-immunoprecipitate with TBP and the TFIIIB complex.[28]

FUS-mediated DNA repair

FUS appears at sites of DNA damage very rapidly, which suggests that FUS is orchestrating the DNA repair response. The function of FUS in the DNA damage response in neurons involves a direct interaction with histone deacetylase 1 (HDAC1). The recruitment of FUS to double-strand break sites is important for DNA damage response signaling and for repair of DNA damage. FUS loss-of-function results in increased DNA damage in neurons. Mutations in the FUS nuclear localization sequence impairs the poly (ADP-ribose) polymerase (PARP)-dependent DNA damage response.[29] This impairment leads to neurodegeneration and FUS aggregate formation. Such FUS aggregates are a pathological hallmark of the neurodegenerative disease amyotrophic lateral sclerosis (ALS).

Clinical significance

FUS gene rearrangement has been implicated in the pathogenesis of myxoid liposarcoma, low-grade fibromyxoid sarcoma, Ewing sarcoma, and a wide range of other malignant and benign tumors (see FET protein family).[30]

In 2009 two separate research groups analysed 26 unrelated families who presented with a type6 ALS phenotype, and found 14 mutations in the FUS gene.[31] [32]

Subsequently, FUS has also emerged as a significant disease protein in a subgroup of frontotemporal dementias (FTDs), previously characterized by immunoreactivity of the inclusion bodies for ubiquitin, but not for TDP-43 or tau with a proportion of the inclusions also containing alpha-internexin (α-internexin) in a further subgroup known as neuronal intermediate filament inclusion disease (NIFID). The disease entities which are now considered subtypes of FTLD-FUS are atypical frontotemporal lobar degeneration with ubiquitinated inclusions (aFTLD-U), NIFID, and basophilic inclusion body disease (BIBD), which together with ALS-FUS comprise the FUS-proteopathies.[33] [34] [35] [36]

Frontotemporal lobar degeneration (FTLD) is the pathological term for the clinical syndrome of frontotemporal dementia (FTD). FTD differs from the more common Alzheimer's dementia in that memory is relatively well preserved; instead, the disease presents with a more temporal-lobe phenotype. Behavioral variant frontotemporal dementia (bvFTD), progressive non-fluent aphasia (PNFA) and semantic dementia (SD) are the three best-characterised clinical presentations. FUS positive FTLD tends to present clinically as a bvFTD but the correlation between underlying pathology and clinical presentation is not perfect.

Toxic mechanism in ALS

The toxic mechanism by which mutant FUS causes ALS is currently unclear. It is known that many of the ALS-linked mutations are located in its C-terminal nuclear localisation signal, resulting in it being located in the cytoplasm rather than the nucleus (where wild-type FUS primarily resides).[37] This suggests either a loss of nuclear function, or a toxic gain of cytoplasmic function, is responsible for the development of this type of ALS. Many researchers believe the toxic gain of cytoplasmic function model to be more likely as mouse models that do not express FUS, and therefore have a complete loss of nuclear FUS function, do not develop clear ALS-like symptoms.[38]

Interactions

FUS has been shown to interact with:

Further reading

Notes and References

  1. Eneroth M, Mandahl N, Heim S, Willén H, Rydholm A, Alberts KA, Mitelman F . Localization of the chromosomal breakpoints of the t(12;16) in liposarcoma to subbands 12q13.3 and 16p11.2 . Cancer Genet Cytogenet . 48 . 1 . 101–7 . Aug 1990 . 2372777 . 10.1016/0165-4608(90)90222-V .
  2. Rabbitts TH, Forster A, Larson R, Nathan P . Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma . Nat Genet . 4 . 2 . 175–80 . Sep 1993 . 7503811 . 10.1038/ng0693-175 . 5964293 .
  3. Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES . TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain . Oncogene . 9 . 12 . 3717–29 . December 1994 . 7970732 .
  4. Web site: Entrez Gene: FUS fusion (involved in t(12;16) in malignant liposarcoma).
  5. Crozat A, Aman P, Mandahl N, Ron D . Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma . Nature . 363 . 6430 . 640–4 . June 1993 . 8510758 . 10.1038/363640a0 . 1993Natur.363..640C . 4358184 .
  6. Mrózek K, Karakousis CP, Bloomfield CD . Chromosome 12 breakpoints are cytogenetically different in benign and malignant lipogenic tumors: localization of breakpoints in lipoma to 12q15 and in myxoid liposarcoma to 12q13.3 . Cancer Res. . 53 . 7 . 1670–5 . April 1993 . 8453640 .
  7. Zinszner H, Albalat R, Ron D . A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP . Genes Dev. . 8 . 21 . 2513–26 . November 1994 . 7958914 . 10.1101/gad.8.21.2513 . free .
  8. Calvio C, Neubauer G, Mann M, Lamond AI . Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry . RNA . 1 . 7 . 724–33 . September 1995 . 7585257 . 1369314 .
  9. Morohoshi F, Ootsuka Y, Arai K, Ichikawa H, Mitani S, Munakata N, Ohki M . Genomic structure of the human RBP56/hTAFII68 and FUS/TLS genes . Gene . 221 . 2 . 191–8 . October 1998 . 9795213 . 10.1016/S0378-1119(98)00463-6 .
  10. Bertolotti A, Bell B, Tora L . The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties . Oncogene . 18 . 56 . 8000–10 . December 1999 . 10637511 . 10.1038/sj.onc.1203207 . free .
  11. Rappsilber J, Friesen WJ, Paushkin S, Dreyfuss G, Mann M . Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode . Anal. Chem. . 75 . 13 . 3107–14 . July 2003 . 12964758 . 10.1021/ac026283q .
  12. Iko Y, Kodama TS, Kasai N, Oyama T, Morita EH, Muto T, Okumura M, Fujii R, Takumi T, Tate S, Morikawa K . Domain architectures and characterization of an RNA-binding protein, TLS . J. Biol. Chem. . 279 . 43 . 44834–40 . October 2004 . 15299008 . 10.1074/jbc.M408552200 . free .
  13. Aman P, Panagopoulos I, Lassen C, Fioretos T, Mencinger M, Toresson H, Höglund M, Forster A, Rabbitts TH, Ron D, Mandahl N, Mitelman F . Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS . Genomics . 37 . 1 . 1–8 . October 1996 . 8921363 . 10.1006/geno.1996.0513 . free .
  14. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D . TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling . J. Cell Sci. . 110 . 15 . 1741–50 . August 1997 . 10.1242/jcs.110.15.1741 . 9264461 .
  15. Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, Salomoni P, Grassilli E, Lozzo RV, Cooper DR, Calabretta B . TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis . EMBO J. . 17 . 15 . 4442–55 . August 1998 . 9687511 . 1170776 . 10.1093/emboj/17.15.4442 .
  16. Baechtold H, Kuroda M, Sok J, Ron D, Lopez BS, Akhmedov AT . Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation . J. Biol. Chem. . 274 . 48 . 34337–42 . November 1999 . 10567410 . 10.1074/jbc.274.48.34337 . free .
  17. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, Tempst P, Rosenfeld MG, Glass CK, Kurokawa R . Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription . Nature . 454 . 7200 . 126–30 . July 2008 . 18509338 . 2823488 . 10.1038/nature06992 . 2008Natur.454..126W .
  18. Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J, Moreau-Gachelin F . Identification of an RNA binding specificity for the potential splicing factor TLS . J. Biol. Chem. . 276 . 9 . 6807–16 . March 2001 . 11098054 . 10.1074/jbc.M008304200 . free .
  19. Fujii R, Takumi T . TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines . J. Cell Sci. . 118 . Pt 24 . 5755–65 . December 2005 . 16317045 . 10.1242/jcs.02692 . free .
  20. Takahama K, Kino K, Arai S, Kurokawa R, Oyoshi T . Identification of RNA binding specificity for the TET-family proteins . Nucleic Acids Symp Ser (Oxf) . 52 . 52 . 213–4 . 2008 . 18776329 . 10.1093/nass/nrn108 . free .
  21. Law WJ, Cann KL, Hicks GG . TLS, EWS and TAF15: a model for transcriptional integration of gene expression . Brief Funct Genomic Proteomic . 5 . 1 . 8–14 . March 2006 . 16769671 . 10.1093/bfgp/ell015 . free .
  22. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH . TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors . Mol. Endocrinol. . 12 . 1 . 4–18 . January 1998 . 10.1210/mend.12.1.0043 . 9440806 . free .
  23. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F . The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS . J. Biol. Chem. . 273 . 9 . 4838–42 . February 1998 . 9478924 . 10.1074/jbc.273.9.4838 . free .
  24. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, Itoh M, Okamoto T . Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator . J. Biol. Chem. . 276 . 16 . 13395–401 . April 2001 . 11278855 . 10.1074/jbc.M011176200 . free .
  25. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L . hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II . EMBO J. . 15 . 18 . 5022–31 . September 1996 . 8890175 . 452240 . 10.1002/j.1460-2075.1996.tb00882.x.
  26. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L . EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes . Mol. Cell. Biol. . 18 . 3 . 1489–97 . March 1998 . 9488465 . 108863 . 10.1128/mcb.18.3.1489.
  27. Yang L, Embree LJ, Hickstein DD . TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins . Mol. Cell. Biol. . 20 . 10 . 3345–54 . May 2000 . 10779324 . 85627 . 10.1128/MCB.20.10.3345-3354.2000 .
  28. Tan AY, Manley JL . TLS inhibits RNA polymerase III transcription . Mol. Cell. Biol. . 30 . 1 . 186–96 . January 2010 . 19841068 . 2798296 . 10.1128/MCB.00884-09 .
  29. Naumann M, Pal A, Goswami A, Lojewski X, Japtok J, Vehlow A, Naujock M, Günther R, Jin M, Stanslowsky N, Reinhardt P, Sterneckert J, Frickenhaus M, Pan-Montojo F, Storkebaum E, Poser I, Freischmidt A, Weishaupt JH, Holzmann K, Troost D, Ludolph AC, Boeckers TM, Liebau S, Petri S, Cordes N, Hyman AA, Wegner F, Grill SW, Weis J, Storch A, Hermann A . Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation . Nat Commun . 9 . 1 . 335 . January 2018 . 29362359 . 5780468 . 10.1038/s41467-017-02299-1 . 2018NatCo...9..335N .
  30. Flucke U, van Noesel MM, Siozopoulou V, Creytens D, Tops BB, van Gorp JM, Hiemcke-Jiwa LS . EWSR1-The Most Common Rearranged Gene in Soft Tissue Lesions, Which Also Occurs in Different Bone Lesions: An Updated Review . Diagnostics (Basel, Switzerland) . 11 . 6 . June 2021 . 1093 . 34203801 . 8232650 . 10.3390/diagnostics11061093 . free .
  31. Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist J, Kasarskis EJ, Munsat T, Valdmanis P, Rouleau GA, Hosler BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Pericak-Vance MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH . Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis . Science . 323 . 5918 . 1205–1208 . February 2009 . 19251627 . 10.1126/science.1166066 . 2009Sci...323.1205K . 12774563 .
  32. Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy D, Wright P, Ganesalingam J, Williams KL, Tripathi V, Al-Saraj S, Al-Chalabi A, Leigh PN, Blair IP, Nicholson G, de Belleroche J, Gallo JM, Miller CC, Shaw CE . Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 . Science . 323 . 5918 . 1208–11 . February 2009 . 19251628 . 10.1126/science.1165942 . 4516382 . 2009Sci...323.1208V .
  33. Mackenzie IR, Rademakers R, Neumann M . TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia . Lancet Neurol . 9 . 10 . 995–1007 . October 2010 . 20864052 . 10.1016/S1474-4422(10)70195-2 . 5754428 .
  34. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR . FUS pathology in basophilic inclusion body disease . Acta Neuropathol. . 118 . 5 . 617–27 . November 2009 . 19830439 . 10.1007/s00401-009-0598-9 . 2429/54671 . 22541167 . free .
  35. Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR . A new subtype of frontotemporal lobar degeneration with FUS pathology . Brain . 132 . Pt 11 . 2922–31 . November 2009 . 19674978 . 2768659 . 10.1093/brain/awp214 .
  36. Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR . Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease . Acta Neuropathol. . 118 . 5 . 605–16 . November 2009 . 19669651 . 2864784 . 10.1007/s00401-009-0581-5 .
  37. Web site: FUS - RNA-binding protein FUS - Homo sapiens (Human) - FUS gene & protein. www.uniprot.org. 2019-03-13.
  38. Kino Y, Washizu C, Kurosawa M, Yamada M, Miyazaki H, Akagi T, Hashikawa T, Doi H, Takumi T, Hicks GG, Hattori N, Shimogori T, Nukina N . FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis . Acta Neuropathologica Communications . 3 . 24 . April 2015 . 25907258 . 4408580 . 10.1186/s40478-015-0202-6 . free .
  39. Wang WY, Pan L, Su SC, Quinn EJ, Sasaki M, Jimenez JC, Mackenzie IR, Huang EJ, Tsai LH . Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons . Nature Neuroscience . 16 . 10 . 1383–91 . October 2013 . 24036913 . 5564396 . 10.1038/nn.3514 .
  40. Saunders LR, Perkins DJ, Balachandran S, Michaels R, Ford R, Mayeda A, Barber GN . Characterization of two evolutionarily conserved, alternatively spliced nuclear phosphoproteins, NFAR-1 and -2, that function in mRNA processing and interact with the double-stranded RNA-dependent protein kinase, PKR . J. Biol. Chem. . 276 . 34 . 32300–12 . August 2001 . 11438536 . 10.1074/jbc.M104207200 . free .
  41. Wada K, Inoue K, Hagiwara M . Identification of methylated proteins by protein arginine N-methyltransferase 1, PRMT1, with a new expression cloning strategy . Biochim. Biophys. Acta . 1591 . 1–3 . 1–10 . August 2002 . 12183049 . 10.1016/S0167-4889(02)00202-1 . free .
  42. Lee J, Bedford MT . PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays . EMBO Rep. . 3 . 3 . 268–73 . March 2002 . 11850402 . 1084016 . 10.1093/embo-reports/kvf052 .
  43. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A, Toksöz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach H, Wanker EE . A human protein-protein interaction network: a resource for annotating the proteome . Cell . 122 . 6 . 957–68 . September 2005 . 16169070 . 10.1016/j.cell.2005.08.029 . 11858/00-001M-0000-0010-8592-0 . 8235923 . free .
  44. Burke KA, Janke AM, Rhine CL, Fawzi NL. Residue-by-Residue View of In Vitro FUS Granules that Bind the C-Terminal Domain of RNA Polymerase II. . Mol. Cell . 60 . 2 . 231–241 . October 15, 2015 . 26455390 . 10.1016/j.molcel.2015.09.006. 4609301 .
  45. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, Than ME, Mackenzie IR, Capell A, Schmid B, Neumann M, Haass C . ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import . EMBO J. . 29 . 16 . 2841–57 . August 2010 . 20606625 . 2924641 . 10.1038/emboj.2010.143 .
  46. Martin Rossor. Brelstaff J, Lashley T, Holton JL, Lees AJ, Rossor MN, Bandopadhyay R, Revesz T . Transportin1: a marker of FTLD-FUS . Acta Neuropathol. . 122 . 5 . 591–600 . November 2011 . 21847626 . 10.1007/s00401-011-0863-6 . 5913873 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RNA-binding protein FUS".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.